Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 25;108(10):2664–2676. doi: 10.3324/haematol.2022.281869

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2023 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 5. — Ex vivo drug response phenotype related to the epistatic interaction between immunoglobulin heavy variable gene status and trisomy 12. (A) Heatmap plot showing the responses of chronic lymphocytic leukemia (CLL) samples (rows) towards the 6 drugs (columns) for which there was a significant interaction between immunoglobulin heavy variable (IGHV) gene mutation status and trisomy 12. The coloring encodes the column-wise z-scores of sample viabilities after drug treatment. (B) Boxplots of the viabilities (normalized to dimethyl sulfoxide [DMSO] controls) of CLL samples, stratified by their IGHV and trisomy 12 status, towards the 6 drugs shown in the heatmap. The IGHV-unmutated (IGHV-U) and IGHV-mutated (IGHV-M) groups contain unmutated-CLL (U-CLL) and mutated-CLL (M-CLL) samples, respectively, without trisomy 12. The IGHV-U+tri12 and IGHV-M+tri12 groups contain U-CLL and M-CLL samples, respectively, with trisomy 12.